GSK-Galapagos' autoimmune disease drug enters midstage trials

02/6/2013 | Pharmaceutical Business Review Online · Reuters

GlaxoSmithKline is preparing midstage trials to assess the experimental drug GSK2586184 in patients with systemic lupus erythematosus and chronic plaque psoriasis. GSK2586184, a selective JAK1 molecule, was identified under Galapagos and GSK's osteoarthritis collaboration.

View Full Article in:

Pharmaceutical Business Review Online · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA